BioCurex gains notice of allowance for US patent:
This article was originally published in Clinica
BioCurex has received a notice of allowance on a US patent relating to over 17 claims surrounding diagnostic applications for its tumour marker, RECAF. The marker is found on malignant cells from a variety of cancer types, but is absent in most normal or benign cells, says the Rancho Santa Margarita, California firm. "This patent coverage will afford us the protection to forge alliances with major companies," adds BioCurex' president, Dr Ricardo Moro.